CHRM3 Gene

CHRM3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CHRM3 Gene</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Acetylcholine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Muscarine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Oxotremorine</td>
<td>M1/M2/M3</td>
</tr>
<tr>
<td class="label">Pilocarpine</td>
<td>M3 partial</td>
</tr>
<tr>
<td class="label">Cevimeline</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Bethanechol</td>
<td>M3 > M1/M2</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Atropine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Scopolamine</td>
<td>M1/M3 > M2/M4</td>
</tr>
<tr>
<td class="label">Tolterodine</td>
<td>M3 > M1/M2</td>
</tr>
<tr>
<td class="label">Solifenacin</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Darifenacin</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Tiotropium</td>
<td>M1/M3/M4</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>M1 (CHRM1)</td>
</tr>
<tr>
<td class="label">G Protein</td>
<td>Gq</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>High (cortex, hippocampus)</td>
</tr>
<tr>
<td class="label">Primary CNS Role</td>
<td>Memory, plasticity</td>
</tr>
<tr>
<td class="label">

CHRM3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CHRM3 Gene</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Acetylcholine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Muscarine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Oxotremorine</td>
<td>M1/M2/M3</td>
</tr>
<tr>
<td class="label">Pilocarpine</td>
<td>M3 partial</td>
</tr>
<tr>
<td class="label">Cevimeline</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Bethanechol</td>
<td>M3 > M1/M2</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Atropine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Scopolamine</td>
<td>M1/M3 > M2/M4</td>
</tr>
<tr>
<td class="label">Tolterodine</td>
<td>M3 > M1/M2</td>
</tr>
<tr>
<td class="label">Solifenacin</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Darifenacin</td>
<td>M3 selective</td>
</tr>
<tr>
<td class="label">Tiotropium</td>
<td>M1/M3/M4</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>M1 (CHRM1)</td>
</tr>
<tr>
<td class="label">G Protein</td>
<td>Gq</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>High (cortex, hippocampus)</td>
</tr>
<tr>
<td class="label">Primary CNS Role</td>
<td>Memory, plasticity</td>
</tr>
<tr>
<td class="label">Peripheral Role</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Therapeutic Target</td>
<td>AD</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CHRM3 (Cholinergic Receptor Muscarinic 3) encodes the M3 muscarinic acetylcholine receptor, a Gq protein-coupled receptor expressed throughout the central and peripheral nervous systems. While M3 receptors are well-known for their roles in smooth muscle contraction, glandular secretion, and autonomic function, growing evidence demonstrates important functions in the central nervous system, including contributions to learning, memory, and synaptic plasticity.

The M3 receptor is distinguished from other muscarinic subtypes by its distribution pattern, pharmacological profile, and physiological functions. In the peripheral nervous system, M3 mediates parasympathetic responses including urinary bladder contraction, gastrointestinal motility, and salivary secretion. In the brain, M3 is expressed in regions involved in cognition and movement, though its functions are less well-characterized than M1 and M4 receptors.

This comprehensive review examines the structure, signaling mechanisms, expression patterns, and physiological functions of CHRM3, with particular emphasis on its roles in the central nervous system and potential relevance to neurodegenerative diseases.

Gene and Protein Structure

Gene Organization

The CHRM3 gene (Gene ID: 1129) is located on chromosome 1q41 and encodes a 532-amino acid protein. The gene structure includes:

• Promoter region: Contains response elements for various transcription factors
• Coding sequence: Single exon encoding the complete receptor protein
• Regulatory elements: Sites for activity-dependent and developmental regulation

Protein Architecture

The M3 muscarinic receptor follows the canonical seven-transmembrane GPCR fold:

Structural Features:

• N-terminal extracellular domain: Contains glycosylation sites important for folding and trafficking
• Transmembrane domain: Seven α-helices (TM1-TM7) forming the ligand-binding pocket
• Extracellular loops: Three loops participating in ligand recognition
• Intracellular loops: Three loops mediating G protein coupling and regulatory phosphorylation
• C-terminal tail: Contains serine/threonine residues for desensitization

Ligand Binding

The M3 receptor binds acetylcholine and various pharmacological ligands:

• Orthosteric site: Deep within the transmembrane domain
• Key binding residues: Conserved aspartic acid in TM3 serves as primary agonist anchor
• Allosteric sites: Additional binding sites for modulatory compounds

Post-Translational Modifications

M3 undergoes several modifications:

• N-linked glycosylation: At N-terminal asparagine residues
• Palmitoylation: At cysteine in C-terminal tail
• Phosphorylation: At serine/threonine residues for desensitization

Signaling Pathways

Primary Gq/11 Signaling

CHRM3 predominantly couples to Gq/11 proteins, activating phospholipase Cβ (PLCβ):

• IP3 Production: Triggers calcium release from endoplasmic reticulum
• DAG Generation: Activates protein kinase C isoforms

• Calmodulin and calmodulin-dependent kinases
• Various calcium-dependent ion channels
• Transcription factors and gene expression

• Phosphorylation of ion channels
• Modulation of receptor function
• Regulation of cellular responses

G Protein Coupling Specificity

The M3 receptor exhibits specific G protein coupling:

Gq/11 Family Members: CHRM3 primarily activates:

• Gαq (GNAQ) - most abundant in most tissues
• Gα14 (GNA14) - more restricted expression
• Gα15/Gα16 (GNA15) - hematopoietic cell expression

• Cell type and receptor density
• Agonist efficacy and concentration
• Receptor phosphorylation state
• Availability of G protein subunits

Second Messenger Dynamics

The second messenger systems activated by M3 have characteristic dynamics:

Calcium Signaling: IP3-mediated calcium release is rapid but transient:

• Calcium release peaks within seconds
• Calcium is quickly cleared by pumps and exchangers
• oscillatory calcium signals can encode information
• Store-operated calcium entry replenishes ER calcium

• Multiple isoforms have different substrate specificities
• PKC can phosphorylate ion channels, receptors, and transcription factors
• Sustained PKC activation leads to desensitization

Secondary Signaling Pathways

M3 activates additional cascades:

• Gq-PLCβ-PKC-ras-RAF-MEK-ERK
• β-arrestin-dependent ERK activation
• Transactivation of receptor tyrosine kinases

• Gβγ subunits can activate PI3K
• Akt promotes cell survival and metabolism
• Cross-talk with other growth factor pathways

• M3 can activate Gs in some cell types
• PKC can modulate adenylyl cyclase activity
• cAMP and Ca2+ pathways interact

β-Arrestin Signaling

Like other GPCRs, M3 signals through β-arrestin adapters:

• Receptor internalization via clathrin-coated pits
• ERK activation through β-arrestin scaffolds
• Akt signaling and cell survival
• β-arrestin-dependent bias can be therapeutically exploited

Signaling Termination

M3 signaling is terminated through multiple mechanisms:

Receptor Desensitization:

• GRK phosphorylation of the C-terminal tail
• β-arrestin binding blocks G protein coupling
• Receptor internalization removes it from the membrane

• IP3 is quickly phosphorylated or degraded
• DAG is metabolized by lipases or kinases
• Calcium is sequestered back into stores

• Internalized receptors can be recycled to the membrane
• Alternatively, receptors can be targeted for degradation
• Lysosomal and proteasomal pathways are involved

M3 Signaling in Different Cell Types

The outcome of M3 activation varies by cell type:

Neurons: In neurons, M3 activation typically causes:

• Increased neuronal excitability
• Enhanced neurotransmitter release
• Activation of transcription factors (CREB)
• Modulation of ion channel function

• Contraction through myosin light chain kinase
• Proliferation in some contexts

Glandular Cells: In secretory cells:

• Enhanced secretion of enzymes, mucus, or other products
• Increased fluid transport
• Apical membrane trafficking

Expression Patterns

Peripheral Nervous System

CHRM3 is highly expressed in peripheral organs:

Central Nervous System

M3 expression in the brain includes:

Cellular Distribution

M3 is expressed in:

• Neurons: Both excitatory and inhibitory
• Glia: Astrocytes and microglia to limited extent
• Smooth muscle cells: Peripheral organs
• Epithelial cells: Glandular tissue

Physiological Functions

Peripheral Functions

Urinary Bladder:
M3 receptors are the primary mediators of bladder contraction:

• Direct activation of detrusor smooth muscle
• Critical for voiding function
• Antagonists used to treat overactive bladder

• Smooth muscle contraction
• Gastrointestinal motility
• Secretory responses

• Salivation
• Bronchoconstriction
• Pupillary constriction
• Gastrointestinal secretion

Central Nervous System Functions

Learning and Memory:
M3 contributes to cognitive processes:

• Synaptic plasticity in hippocampus
• Object recognition memory
• Spatial learning

• Modulation of striatal neuron activity
• Potential relevance to movement disorders

• Status epilepticus involvement
• Anti-seizure drug targets

• Pro-survival signaling
• Modulation of excitotoxicity

Disease Associations

Overactive Bladder

M3 antagonists are first-line treatments:

• Tolterodine, solifenacin, darifenacin
• Reduce bladder contractility
• Improve urinary frequency and urgency

Chronic Obstructive Pulmonary Disease

M3 antagonists in respiratory therapy:

• Bronchodilation
• Reduced mucus secretion

Dry Mouth (Xerostomia)

M3 agonists can stimulate saliva:

• Pilocarpine, cevimeline
• Used for Sjögren's syndrome and radiation-induced dry mouth

Gastrointestinal Disorders

M3 modulators for:

• Irritable bowel syndrome
• Constipation
• Gastroparesis

Alzheimer's Disease

M3 has been investigated for AD treatment:

Epilepsy

M3 plays complex roles in seizure disorders:

Parkinson's Disease

M3 may contribute to:

• Motor and non-motor symptoms
• Potential for therapeutic targeting

Therapeutic Targeting

Agonists

M3 agonist clinical applications:

• Pilocarpine: FDA-approved for dry mouth (Salagen)
• Cevimeline: Dry mouth in Sjögren's syndrome
• Bethanechol: Urinary retention

• Lack of subtype selectivity
• Peripheral side effects
• Limited CNS penetration

Antagonists

M3 antagonist applications:

• Overactive bladder: Tolterodine, solifenacin
• COPD: Tiotropium (also M1/M4 activity)
• Gastrointestinal: Various antispasmodics

• M3 antagonists often affect other muscarinic subtypes
• Side effects related to non-selective action

Selective Modulators

Newer approaches aim for greater selectivity:

CNS Function and Neurodegeneration

Memory Formation

M3 contributes to memory through:

• LTP induction and maintenance
• NMDA receptor modulation
• Calcium signaling cascades

• CREB activation and gene expression
• Protein kinase activation
• Synaptic protein regulation

• M3 knockout mice show memory deficits
• M3 agonists enhance memory in models

Neurodegenerative Disease Relevance

Alzheimer's Disease:

M3 may be relevant to AD pathophysiology:

• Cholinergic deficiency affects M3 signaling
• Amyloid-β interactions with muscarinic receptors
• Potential for therapeutic modulation

M3 in PD research:

• Striatal M3 expression and function
• Potential for motor symptom modulation

Interactions with Other Proteins

M3 interacts with:

Cross-Talk

M3 signaling intersects with:

Pharmacology

Agonist Pharmacology

Antagonist Pharmacology

Research Directions

Emerging Areas

Challenges

Future Perspectives

Comparative Analysis

M1 vs M3

M3 vs Other Subtypes

M3 occupies a unique position:

• Gq coupling (like M1, M5)
• Peripheral expression (like M2, M4)
• Intermediate CNS expression
• Dual CNS/peripheral function

M3 in Neuroinflammation

Emerging research indicates CHRM3 plays a role in neuroinflammatory processes:

Microglial Function

M3 receptors on microglia modulate:

• Cytokine production and release
• Phagocytic activity
• Antigen presentation

Astrocyte Signaling

Astrocytic M3 receptors influence:

• Calcium wave propagation
• Glutamate uptake regulation
• Metabolic support functions

Therapeutic Implications

M3 modulation may affect:

• Neuroinflammatory responses in AD and PD
• Excitotoxicity through astrocyte modulation
• Disease progression through immune mechanisms

M3 and Circadian Function

Recent studies reveal M3 exhibits circadian regulation:

Daily Expression Patterns

CHRM3 expression shows:

• Circadian variation in hippocampus
• Time-of-day effects on M3-mediated responses
• Interaction with clock gene pathways

Sleep-Wake Regulation

M3 contributes to:

• Arousal and wakefulness
• REM sleep modulation
• Autonomic regulation during sleep

Genetic Considerations

CHRM3 Polymorphisms

Genetic variations in CHRM3 have been associated with:

• Bladder dysfunction susceptibility
• Cognitive performance variations
• Response to anticholinergic medications

Expression Regulation

CHRM1 expression is regulated by:

• Epigenetic modifications
• Neuronal activity
• Various transcription factors

M3 in Blood-Brain Barrier Function

M3 influences blood-brain barrier (BBB) properties:

Endothelial Cells

M3 signaling affects:

• Tight junction integrity
• Transport mechanisms
• Endothelial cell activation

Neuroimmune Interactions

M3 modulates:

• Leukocyte trafficking
• Inflammatory responses at BBB
• CNS immune privilege

M3 in Metabolic Function

M3 contributes to metabolic regulation:

Glucose Metabolism

M3 activation influences:

• Hepatic glucose production
• Insulin secretion and sensitivity
• Energy expenditure

Body Weight

M3 modulators may affect:

• Food intake regulation
• Energy balance
• Obesity risk

Drug Development Pipeline

Clinical Stage Compounds

• Cevimeline (approved for dry mouth)
• Pilocarpine (approved for dry mouth)

• Tolterodine, solifenacin, darifenacin (OAB)
• Tiotropium (COPD)

Preclinical Development

Development Challenges

Animal Models

Knockout Studies

CHRM3 knockout mice exhibit:

• Urinary bladder dysfunction
• Reduced gastrointestinal motility
• Altered cognitive function in some tests
• Salivary hypofunction

Transgenic Models

Transgenic expression studies reveal:

• M3 overexpression effects on smooth muscle
• Conditional knockout systems
• Disease model interactions

External Links

• [NCBI Gene - CHRM3](https://www.ncbi.nlm.nih.gov/gene/1129) - Gene database entry
• [OMIM - CHRM3](https://www.omim.org/entry/118510) - Online Mendelian Inheritance in Man
• [UniProt - CHRM3](https://www.uniprot.org/uniprotkb/P20333/entry) - Protein sequence data
• [Ensembl - CHRM3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133019) - Genomic resources](/resources)
• [PubMed - CHRM3](https://pubmed.ncbi.nlm.nih.gov/?term=CHRM3+muscarinic+receptor) - Literature search

Summary

CHRM3 encodes the M3 muscarinic acetylcholine receptor, a Gq-coupled GPCR with diverse functions in both the central and peripheral nervous systems. While best characterized for its roles in peripheral organ function including urinary bladder contraction, gastrointestinal motility, and glandular secretion, M3 receptors are increasingly recognized for important functions in the brain. In the central nervous system, CHRM3 contributes to learning and memory processes, synaptic plasticity, and modulation of neuronal excitability. The receptor signals through Gq/11 proteins, activating phospholipase Cβ and generating IP3 and DAG, which lead to calcium release and protein kinase C activation. M3 has been implicated in Alzheimer's disease pathophysiology through cholinergic deficiency, amyloid-β interactions, and potential effects on amyloid processing. Additionally, M3 plays roles in neuroinflammation, circadian regulation, and blood-brain barrier function. Several M3-targeted drugs are in clinical use, including antagonists for overactive bladder (tolterodine, solifenacin, darifenacin) and agonists for dry mouth (pilocarpine, cevimeline). Ongoing research focuses on developing more selective M3 modulators, understanding M3's role in neurodegeneration, and exploring M3-targeted approaches for AD and other neurological disorders.

References